845 related articles for article (PubMed ID: 21943799)
21. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
22. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Shimada YJ; Cannon CP
Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
[TBL] [Abstract][Full Text] [Related]
23. Recent patents on PCSK9: a new target for treating hypercholesterolemia.
Li H; Li H; Ziegler N; Cui R; Liu J
Recent Pat DNA Gene Seq; 2009; 3(3):201-12. PubMed ID: 19601924
[TBL] [Abstract][Full Text] [Related]
24. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
25. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
26. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
27. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Awan Z; Baass A; Genest J
Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
[TBL] [Abstract][Full Text] [Related]
28. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
30. Unravelling the functional significance of PCSK9.
Lambert G
Curr Opin Lipidol; 2007 Jun; 18(3):304-9. PubMed ID: 17495605
[TBL] [Abstract][Full Text] [Related]
31. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
Schulz R; Schlüter KD; Laufs U
Basic Res Cardiol; 2015 Mar; 110(2):4. PubMed ID: 25600226
[TBL] [Abstract][Full Text] [Related]
32. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
Norata GD; Tibolla G; Catapano AL
Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410
[TBL] [Abstract][Full Text] [Related]
33. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
34. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
[TBL] [Abstract][Full Text] [Related]
35. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
36. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang E
Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
[TBL] [Abstract][Full Text] [Related]
37. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
Ferdinand KC; Nasser SA
Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
[TBL] [Abstract][Full Text] [Related]
38. PCSK9: an enigmatic protease.
Lopez D
Biochim Biophys Acta; 2008 Apr; 1781(4):184-91. PubMed ID: 18280815
[TBL] [Abstract][Full Text] [Related]
39. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
